O
APGE icon

OrbiMed’s Apogee Therapeutics APGE Stock Holding History

OrbiMed’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-379,130
Closed -$22.3M – 121
2024
Q3 		$22.3M Hold
379,130
– – 0.4% 63
2024
Q2 		$14.9M Sell
379,130
-339,771
-47% -$16.5M 0.29% 63
2024
Q1 		$47.8M Sell
718,901
-559,000
-44% -$24.4M 0.87% 41
2023
Q4 		$35.7M Sell
1,277,901
-150,000
-11% -$3.01M 0.71% 49
2023
Q3 		$30.4M Buy
+1,427,901
New +$31.5M 0.65% 57

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

OrbiMed's APGE Position: Q4 2024 in Review

OrbiMed sold out of Apogee Therapeutics (APGE) in Q4 2024, closing a stake of 379,130 shares — an estimated $22.3M sold.

OrbiMed first reported a position in APGE in Q3 2023 and held it in 5 quarters. The position peaked at $47.8M in Q1 2024. 157 funds tracked by Wall St. Rank hold APGE as of Q4 2024.

  • OrbiMed reported no remaining Apogee Therapeutics position as of Q4 2024 after selling out during the quarter.
  • OrbiMed sold 379,130 Apogee Therapeutics shares in Q4 2024, an estimated $22.3M.
  • OrbiMed first reported a position in Apogee Therapeutics in Q3 2023 and held it in 5 quarters.
  • OrbiMed's Apogee Therapeutics position peaked at $47.8M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.